Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition

New England Journal of Medicine

DOI: 10.1056/nejmra2201664 OpenAlex

Authors 0

Author list not loaded yet.

Cited by 11 stored of 113

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles
2026 European Journal of Immunology article Immunology and Microbiology Complement system in diseases Open access

1

citations
Insights in bone marrow failure syndromes: take home messages from the 3rd ESH-EBMT-EHA-IPIG translational research conference
2025 Bone Marrow Transplantation article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access

1

citations
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
2025 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access

15

citations
Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH
2024 Blood article Immunology and Microbiology Complement system in diseases Open access

27

citations
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
2024 Transfusion Medicine and Hemotherapy article Immunology and Microbiology Complement system in diseases Open access

8

citations
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity
2024 Frontiers in Immunology article Immunology and Microbiology Complement system in diseases Open access cited by 2 patents

16

citations
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
2024 Blood Advances article Immunology and Microbiology Complement system in diseases Open access

18

citations
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
2024 Hematology article Immunology and Microbiology Complement system in diseases Open access

22

citations
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH
2024 Blood Advances article Immunology and Microbiology Complement system in diseases Open access

34

citations
Paroxysmal nocturnal hemoglobinuria: Where we stand
2023 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access

24

citations
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target
2022 Immunological Reviews review Immunology and Microbiology Complement system in diseases Open access

52

citations

11 results

References 3

3 results